Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherInvited Perspectives

Imaging MAO-A Levels by PET Using the Deuterium Isotope Effect

Ronald M. Baldwin
Journal of Nuclear Medicine September 2005, 46 (9) 1411-1413;
Ronald M. Baldwin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

The measurement of enzyme levels by noninvasive imaging is of great value, similar to results from imaging cell surface–bound receptors, such as dopamine, serotonin, and so on, which have shone light on many disorders (1–3). Unlike receptor targets for imaging, however, enzymes consume their substrates and thus involve not only binding but also catalytic activity. This gives an added dimension to radiotracer imaging, both as a challenge and as an opportunity. In this issue of The Journal of Nuclear Medicine (pages 1414–1420), Fowler et al. (4) apply PET of the enzyme monoamine oxidase A (MAO-A) using the deuterium isotope effect with 11C-clorgyline and 11C-clorgyline-D2 to study an important epidemiologic area, the effect of smoking on the lungs.

MONOAMINE OXIDASE (MAO)

MAO is one of a class of metabolic enzymes involved in the disposition of biogenic and xenobiotic amines by oxidative metabolism. In common with other amine oxidases, such as copper amine oxidase and benzylamine oxidase, MAO catalyzes the oxidation of the α-carbon of aliphatic amines, resulting in scission of the C—N bond and producing the corresponding aldehyde or ketone and amine (or ammonia) (Fig. 1).

  FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

Diagrammatic mechanism of MAO-catalyzed amine oxidation.

The enzyme was discovered and its biochemical scope was determined in the middle of the 20th Century (5). In 1988, Johnston (6) described 2 subtypes of the enzyme based on their selective inhibition. Subtype A (MAO-A) is inhibited by clorgyline and preferentially catalyzes oxidation of serotonin, whereas MAO-B is inhibited by l-deprenyl and preferentially acts on phenethylamine and benzylamine. Subsequent work has shown that the isozymes are distinct proteins coded by separate genes, although they share considerable homology in their genetic sequence (7). The proposed mechanism of MAO-catalyzed oxidation outlined in Figure 1 involves formation of a substrate–enzyme complex and oxidation via a flavin adenine dinucleotide (FAD) cofactor to an imine (Schiff’s base), which hydrolyzes to the corresponding aldehyde or ketone and residual amine, or ammonia if the original amine was primary (8). MAO inhibitors (MAOI) have applications as therapeutic drugs—for instance, in the treatment of depression (9) and Parkinson’s disease (10). Patients receiving MAOI therapy are admonished to avoid fermented food such as cheese to avoid hypertensive episodes (so-called tyramine crises or the “cheese effect”) (11,12) that result from inhibition of metabolism of the vasoactive constituent tyramine. Dietary tyramine is normally metabolized by MAO, largely by MAO-A in the intestinal wall (13).

DEUTERIUM ISOTOPE EFFECT

It is a basic tenet of isotopic tracer theory that isotopes of an element, having the same number of protons but a different number of neutrons, have the same chemical properties. Chemical properties are controlled by the configuration of orbital electrons, the number of which is determined by the number of protons in the nucleus. Nevertheless, the atomic mass (determined by the number of protons plus neutrons) does have an effect on certain chemical properties that depend on bond deformation, such as infrared absorption bands and rates of bond-making or -breaking reactions. Thus, whereas compounds with different isotopic composition undergo the same chemical reaction pathways, the rates of these reactions are not precisely the same, an example of the ponderal effect—that is, physicochemical properties influenced by differences in mass. The isotope effect is greater in the lighter elements, where the relative change in atomic mass is greater, and greatest in the lightest element, hydrogen, in which adding neutrons to the nucleus doubles or triples the atomic mass for deuterium (2H, D) and tritium (3H, T), respectively. The kinetic isotope effect has become a useful tool in the determination of the mechanism of chemical and biochemical reactions. In general, a large isotope effect indicates that the bond containing the isotopic label is involved in the rate-determining step—that is, the slowest step in a sequence of intermediate reactions. The difference in rate of reaction of isotopomers (compounds that differ only in the isotopic composition of one or more atoms) has even been used as a device to direct synthetic sequences via a deuterated intermediate that does not appear in the final product (14). Amine oxidases show significant isotope effects. Substitution of the α-hydrogen atoms of biogenic amines does not affect binding of the substrate to the enzyme but reduces the rate of oxidation by factors up to 5.5 (8). Studies of stereospecifically labeled amines have shown that MAO selectively catalyzes loss of the pro-R α-hydrogen atom (Fig. 1), in contrast to other amine oxidases, which affect the pro-S atom or are not selective (15).

DUAL-TRACER MAO IMAGING

Fowler and coworkers at Brookhaven National Laboratory (4) have used these properties to design radiotracer suites to improve in vivo quantitation and help define specific uptake, generating radiotracers for MAO-A (11C-clorgyline and its deutero analog 11C-clorgyline-D2) (16) and for MAO-B (11C-deprenyl and 11C-deprenyl-D2) (17). In an elegant study design, native enzyme levels are estimated by PET and arterial plasma analysis after administration of 11C-labeled tracer, followed by a second study with the specifically deuterium-substituted isotopomer. By comparing the model-derived measure of MAO activity for the deuterio- versus protio-tracer, additional information about the specificity of radiotracer uptake is obtained. Those areas with greatest difference between deuterium and protium correspond to areas where the radiotracer interacts most directly with the enzyme. A modified 2-tissue, 3-compartment model (18) is used to derive the measure of enzyme activity. In such a model, transfer between arterial plasma and organ is represented by K1 and k2, respectively; the ratio K1/k2, often assigned the designation λ, represents a measure of permeability or tissue uptake. Transfer between nonspecific tracer (combining free and nonspecifically bound) and enzyme-bound tracer is given by rate constants k3 and k4, respectively. Setting the k4 term (rate of dissociation from specifically bound compartment) to zero accounts for the irreversible trapping of radiotracer during metabolic oxidation (19). The k3 term is related not only to specific binding to the protein but also to the catalytic bond-breaking process. For most tissues, the most robust model parameter was found to be the product λk3 except for the lung, where k3 alone was more reliable. This phenomenon has been investigated further and found to be related to the larger permeability term (K1/k2) in smokers (20).

Thanks to the short half-life of the 11C label (20.2 min), both the protio- and deuterio-forms of the radiotracer can be studied in the same individual within a few hours, thus avoiding the confound of changing physiologic states on different days and the risk of losing a study because the subject fails to return for the follow-up scan. To perform such a program effectively requires substantial development and validation of methods, to provide the capability to synthesize multiple tracers for radiopharmaceutical administration in a short time, perform rapid and accurate plasma analysis for unmetabolized tracer, and perform quantitative PET acquisition and analysis. The Brookhaven group has demonstrated this paradigm in a series of basic and applied papers (16,17,19,21–23) in the study of MAO-A and MAO-B in brain and peripheral organs.

The results of applying this paradigm to MAO-A activity in lungs, as reported in this issue of the Journal, has revealed insights into the effects of smoking that go beyond the obvious and direct effects of nicotine and other major components of tobacco smoke. As the authors point out, among the main effects of smoking, smoking exerts synergistic effects so as to increase the plasma levels of vasoactive amines, both by stimulating their release and by inhibiting their metabolism and clearance through inhibition of MAO activity. Overall, this study report, which may be viewed as the culmination of a large body of work to lay the foundation and develop the data, has revealed intriguing facets of the effect of smoking on the lungs. As in many scientific investigations, the questions it has raised may turn out to be more informative than the questions it answers. In any event, these techniques provide tools that promise to lead to a broader understanding of the biochemistry of amine metabolism in vivo.

Footnotes

  • Received Jul. 12, 2005; revision accepted Jul. 15, 2005.

    For correspondence or reprints contact: Ronald M. Baldwin, PhD, Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center/PET Chemistry, 1161 21st Ave. South, Nashville, TN 37232-2765.

    E-mail: ronald.baldwin{at}vanderbilt.edu

REFERENCES

  1. ↵
    Wagner HN Jr. Quantitative imaging of neuroreceptors in the living human brain. Semin Nucl Med. 1986;16:51–62.
    OpenUrlPubMed
  2. Phelps ME. Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci USA. 2000;97:9226–9233.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metabol. 2000;20:423–451.
    OpenUrlPubMed
  4. ↵
    Fowler JS, Logan J, Wang G-J, et al. Comparison of monoamine oxidase A in peripheral organs in nonsmokers and smokers. J Nucl Med. 2005;46:1414–1420.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Kopin IJ. Monoamine oxidase and catecholamine metabolism. J Neural Transm Suppl. 1994;41:57–67.
    OpenUrlPubMed
  6. ↵
    Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol. 1968;17:1285–1297.
    OpenUrlCrossRefPubMed
  7. ↵
    Shih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes to behavior. Annu Rev Neurosci. 1999;22:197–217.
    OpenUrlCrossRefPubMed
  8. ↵
    Olsson B, Olsson J, Pettersson G. Kinetic isotope effects on the catalytic activity of pig-plasma benzylamine oxidase. Eur J Biochem. 1976;64:327–331.
    OpenUrlPubMed
  9. ↵
    Vetulani J, Nalepa I. Antidepressants: past, present and future. Eur J Pharmacol. 2000;405:351–363.
    OpenUrlCrossRefPubMed
  10. ↵
    Mizuno Y, Mori H, Kondo T. Potential of neuroprotective therapy in Parkinsons disease. CNS Drugs. 1994;1:45–56.
  11. ↵
    Knoll J. The pharmacological profile of (-)deprenyl (selegiline) and its relevance for humans: a personal view. Pharmacol Toxicol. 1992;70:317–321.
    OpenUrlPubMed
  12. ↵
    Caldecott-Hazard S, Schneider LS. Clinical and biochemical aspects of depressive disorders. III. Treatment and controversies. Synapse. 1992;10:141–168.
    OpenUrlCrossRefPubMed
  13. ↵
    Anderson MC, Hasan F, McCrodden JM, Tipton KF. Monoamine oxidase inhibitors and the cheese effect. Neurochem Res. 1993;18:1145–1149.
    OpenUrlCrossRefPubMed
  14. ↵
    Dudley GB, Danishefsky SJ, Sukenick G. On the use of deuterium isotope effects in chemical synthesis. Tetrahedron Lett. 2002;43:5605–5606.
    OpenUrl
  15. ↵
    Yu PH. Three types of stereospecificity and the kinetic deuterium isotope effect in the oxidative deamination of dopamine as catalyzed by different amine oxidases. Biochem Cell Biol. 1988;66:853–861.
    OpenUrlPubMed
  16. ↵
    Fowler JS, Ding Y-S, Logan J, et al. Species differences in [11C]clorgyline binding in brain. Nucl Med Biol. 2001;28:779–785.
    OpenUrlCrossRefPubMed
  17. ↵
    Fowler JS, Wang GJ, Logan J, et al. Selective reduction of radiotracer trapping by deuterium substitution: comparison of carbon-11 L-deprenyl and carbon-11-deprenyl-D2 for MAO B mapping. J Nucl Med. 1995;36:1255–1262.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Ichise M, Meyer JH, Yonekura Y. An introduction to PET and SPECT neuroreceptor quantification models. J Nucl Med. 2001;42:755–763.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Fowler JS, Logan J, Wang G-J, et al. Comparison of the binding of the irreversible monoamine oxidase tracers, [11C]clorgyline and [11C]L-deprenyl in brain and peripheral organs in humans. Nucl Med Biol. 2004;31:313–319.
    OpenUrlCrossRefPubMed
  20. ↵
    Logan J, Fowler JS. Evidence for reduced arterial plasma input, prolonged lung retention and reduced lung monoamine oxidase in smokers. Nucl Med Biol. 2005;32:521–529.
    OpenUrlCrossRefPubMed
  21. ↵
    Fowler JS, Wolf AP, MacGregor RR, et al. Mechanistic positron emission tomography studies: demonstration of a deuterium isotope effect in the monoamine oxidase-catalyzed binding of [11C]L-deprenyl in living baboon brain. J Neurochem. 1988;51:1524–1534.
    OpenUrlCrossRefPubMed
  22. Fowler JS, Logan J, Wang G-J, et al. PET imaging of monoamine oxidase B in peripheral organs in humans. J Nucl Med. 2002;43:1331–1338.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Fowler JS, Logan J, Wang G-J, et al. Monoamine oxidase A imaging in peripheral organs in healthy human subjects. Synapse. 2003;49:178–187.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 46 (9)
Journal of Nuclear Medicine
Vol. 46, Issue 9
September 1, 2005
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Imaging MAO-A Levels by PET Using the Deuterium Isotope Effect
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Imaging MAO-A Levels by PET Using the Deuterium Isotope Effect
Ronald M. Baldwin
Journal of Nuclear Medicine Sep 2005, 46 (9) 1411-1413;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Imaging MAO-A Levels by PET Using the Deuterium Isotope Effect
Ronald M. Baldwin
Journal of Nuclear Medicine Sep 2005, 46 (9) 1411-1413;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • MONOAMINE OXIDASE (MAO)
    • DEUTERIUM ISOTOPE EFFECT
    • DUAL-TRACER MAO IMAGING
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • THIS MONTH IN JNM
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Radiomics in PET/CT: More Than Meets the Eye?
  • Metabolic Tumor Volume: We Still Need a Platinum-Standard Metric
  • Citius, Altius, Fortius: An Olympian Dream for Theranostics
Show more Invited Perspectives

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire